Nowadays, immunotherapies, particularly immune checkpoint inhibition (ICI) of CTLA4 and PD1/PDL1, are increasingly used as a promising and effective systemic cancer treatment, boosting the immune response, and thus leading to successful immune recognition and tumor cell killing [21,22,23]. Here, PDCD1 is linked to neoplasm.